Our results demonstrate that human presence acutely affects same-day wildlife detections in protected areas, supporting the hypothesis that avoidance behaviour is a type of "mortality-free predation".
As in the initial report, the 5-year cancer-specific mortality-free rate was used for comparisons [2].
The 5-year cancer-specific mortality-free rate was 78.0%9595% CI = 71.3% to 85.4%) in our group.
The MACEs and all-cause mortality-free survival curves of patients with and without ISMN therapy are shown in Figure 1 and 2, respectively.
The first nomogram to predict the 5-year cancer-specific mortality-free rate was developed by Kattan et al. [13] and had a C-index of 0.747 in the initial cohort.
Tumor grade was classified using the 3-grade Broders scale [9], and the cancer-specific mortality-free survival was defined as the interval between the surgery date and cancer-related death or last follow-up date for censored patients.
Instead of the QALY, three outcome measures have been considered in this study: overall mortality, survival free of morbidity and survival free of long-term morbidity, all considered over a maximum of 2 years.
Secondary endpoints were identified as organ dysfunction and failure occurring after admission to the intensive care unit (Δ-SOFA), 28-day all-cause mortality, days free from intensive care unit, organ support-free days, and measurement and correlation with adrenal insufficiency.
To illuminate the statistical efficiency of POD + death, we compared the sample size requirements based on POD + death to the traditional endpoints of 28-day mortality, ventilator free days (VFD) [ 12], and organ-failure free days (OFFD) [ 3] at 28 days.
The secondary outcomes were hospital mortality, ventilator-free days, vasopressor-free days, duration of mechanical ventilation, ICU and hospital length of stay and the need for renal replacement therapy (RRT), including continuous veno-venous hemofiltration or intermittent hemodialysis.
Recently, in two large, multicenter, double-blind, randomized, placebo-controlled studies, simvastatin and rosuvastatin did not improve clinical outcomes in patients with ARDS or sepsis-associated ARDS (28- or 60-day inhospital mortality, ventilator-free days, or days free of nonpulmonary organ failure) [ 11, 12].
